References
  1. Wendelboe et al. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 118 , 1340-1347 (2016)
  2. Ceornodolea et al. Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Res Treat 2017 , 8593207 (2017)
  3. https://www.dutchthrombosisnetwork.org/
  4. Vrijens et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 73, 691-705 (2012)
  5. Banerjee et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population based study. Heart106 ,119–126 (2020)
  6. Zielinski et al. Therapietrouw van patiënten met atriumfibrilleren voor direct werkende orale anticoagulantia. Ned Tijdsch Geneeskd.164 , D44775 (2020)
  7. Capiau et al. Community pharmacy-based study of adherence to non-vitamin K antagonist oral anticoagulants. Heart. 106 , 1740-1746 (2020)
  8. Ruff et al. The Role of Adherence Thresholds for Development and Performance Aspects of a Prediction Model for Direct Oral Anticoagulation Adherence. Frontiers in pharmacology 10 , 113 (2019)
  9. Bartoli-Abdou et al. Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. Throm Res. 208 , 162-169 (2021)
  10. Toorop et al. Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants. Res Pract Thromb Haemost. 4 , 586-593 (2020)
  11. Ozaki et al. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes 13,E005969 (2020)
  12. Rolfes et al. Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: a web-based cohort event monitoring study. Expert Opinion on Drug Safety 18 , 869-874 (2019)
  13. Lèan Rolfes en Corine Ekhart. Bijwerkingen van DOAC’s herstellen meestal spontaan. Pharm weekbl 154 , 14-18 (2018)
  14. Mitrovic et al. Minor bleeding in patients with artrial fibrillation using a non-vitamine-K antagonist oral anticoagulant. Curr Med Res Opin. 36 , 1571-1576 (2020)
  15. Mitrovic et al. Impact of minor bleeds on confidence in anticoagulation therapy, adherence to treatment and quality of life in patients using a non-vitamin K antagonist oral anticoagulant for artrial fibrillation. Curr Med Res Opin. 38, 1485-1488 (2022)
  16. Mitrovic et al. Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation. Curr Med Res Opin. 36 , 547-553 (2020).
  17. Horne et al. The Medication Adherence Report Scale: A measurement tool for eliciting patients’ reports of nonadherence. Br J Clin Pharmacol.86 , 1281-1288 (2020).
  18. Horne et al. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 47 , 555-567 (1999).
  19. Tommelein et al. Accuracy of the Medication Adherence Report Scale (MARS-5) as a quantitative measure of adherence to inhalation medication in patients with COPD. Ann Pharmacoth. 48 , 589-595 (2015)
  20. Huiskes et al. Impact of physician’ and pharmacy staff supporting activities in usual care and patients’ statin adherence. PLoS One17 , e0264555 (2022)
  21. Geffen et al. Patients’ satisfaction with information and experiences with counseling on cardiovascular medication received at the pharmacy. Patient Educ Couns. 83 , 303-309 (2011)
Appendix 1. Associations between patients’ adherence to DOACs and baseline characteristics